Prestige Consumer Healthcare (NYSE:PBH) Upgraded at StockNews.com

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a buy rating in a research note published on Tuesday.

PBH has been the subject of several other research reports. DA Davidson boosted their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Canaccord Genuity Group boosted their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a report on Monday, December 9th. Finally, Oppenheimer boosted their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday, February 13th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $92.60.

Prestige Consumer Healthcare Stock Up 0.7 %

PBH stock opened at $84.22 on Tuesday. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $4.17 billion, a PE ratio of 19.72, a PEG ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare has a twelve month low of $62.35 and a twelve month high of $90.04. The stock has a 50-day simple moving average of $82.25 and a two-hundred day simple moving average of $78.53.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, equities analysts predict that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the sale, the senior vice president now owns 17,157 shares in the company, valued at $1,544,130. The trade was a 8.91 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Kestra Investment Management LLC bought a new stake in Prestige Consumer Healthcare in the fourth quarter valued at approximately $27,000. CIBC Private Wealth Group LLC lifted its position in Prestige Consumer Healthcare by 48.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after purchasing an additional 152 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $40,000. Huntington National Bank increased its stake in shares of Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after buying an additional 181 shares during the period. Finally, McIlrath & Eck LLC increased its stake in shares of Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock valued at $75,000 after buying an additional 154 shares during the period. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.